CD44 plays a critical role in the progression and metastasis of docetaxel‐resistant prostate cancer cells through the Hippo–YAP pathway, which could represent a potential treatment target in docetaxel‐resistant prostate cancer.199. Here, CD44 is linked to prostate carcinoma.